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A diverse library of cationic silver complexes bearing bis(N-heterocyclic carbene) ligands have been
prepared which exhibit cytotoxicity comparable to cisplatin against the adenocarcinomas MCF7 and
DLD1. Bidentate ligands show enhanced cytotoxicity over monodentate and macrocyclic ligands.
Introduction
Over the past two decades metal complexes of N-heterocyclic
carbenes (NHCs) have become extremely important in catalytic
processes such as cross-coupling, metathesis, C–H bond acti-
vation and polymerisation.1–4 To a much lesser extent they have
been investigated in biomedical applications, showing promise
as antimicrobial (silver–NHCs) and as antitumour agents.5–7
The antimicrobial properties of silver are well established and
have resulted in silver being incorporated into several materials
such as wound dressings, creams, deodorants and even
clothing.8–10 The toxicity of silver is thought to be relatively low
which has enabled its wide use. Silver–NHC complexes are
emerging as new and improved antimicrobial agents to overcome
problems associated with conventional silver antibiotics such as
fast loss of activity and resistance.5,11–13 It has been suggested
that the increased stability of silver NHCs results in a slower
release of silver, rendering the compounds active over a longer
period of time.
Studies have been carried out which indicate that metal–NHC
complexes may also be useful in cancer chemotherapy. Speciﬁ-
cally, NHC complexes of palladium, copper, gold and silver
have been reported which exhibit cytotoxicity against various
cancer cell lines.6,12,14–16 Most of the cytotoxic silver NHCs
reported are neutral complexes, bearing a monodentate NHC
donor and an acetate ligand (Fig. 1A).16–21 Youngs et al. have
reported cationic monodentate NHC complexes that are effective
against the H460 lung cancer cell line, though cytotoxicity was
not superior to cisplatin (Fig. 1B).22 Herein, we report the prep-
aration of a range of chelating and macrocyclic bis-imidazolium
precursors and their coordination to form cationic silver bis
(NHC) complexes (Fig. 3). The cytotoxicity of the complexes
was evaluated against the cancer cell lines MCF7 (breast) and
DLD1 (colon) to assess the effect of bidentate ligands on
activity. The nitrogen substituents (R), position of the carbene
moiety (meta or para) and the counterion (X) were varied to
gain structure–activity relationships. In addition, a monodentate
derivative was prepared and tested to compare the activity of
multidentate ligands compared to their monodentate counter-
parts. Testing of simple silver salts (AgBr, AgBF4), and imidazo-
lium salt precursors in the absence of silver, suggests that both
the silver and the ligand moieties are essential for their activity.
Results and discussion
Imidazolium salts 1–4 were prepared through reaction of an
N-substituted imidazole with a bromomethylated core
(Scheme 1).23,24 Reactions were generally performed in dichloro-
methane, with the bromide salts precipitating within 1 hour.
Counterion exchange was performed using NH4BF4 in methanol.
A characteristic shift of the C2 proton from ∼7.5 to ∼9 ppm in
the 1H NMR spectra of the resulting white solids show the
desired products to have formed.
We have previously reported the coordination of bis(imidazo-
lium) hexaﬂuorophosphate and tetraﬂuoroborate salts to silver
using the common Ag2O route.
24,25 Basic silver oxide reacts
with an imidazolium salt causing in situ deprotonation of the C2
proton and coordination to silver, with concomitant silver salt
formation. The reaction conditions are dependent upon the
ligand used and the counterion, with the tetraﬂuoroborate salts
formed in dimethylsulphoxide at 80 °C. As the C2 proton of the
imidazolium bromide salts is more acidic, reactions to coordinate
the carbene ligand to silver can be performed at room tempera-
ture. Initial reactions were conducted in anhydrous methanol
with the use of molecular sieves to remove the water formed
during the reaction. It was found that the resulting complexes
were air sensitive, with solids becoming oily and depositing a
Fig. 1 Neutral (A) and cationic (B) cytotoxic silver NHCs.
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dark brown solid. Elemental analyses conﬁrmed that the com-
plexes contained large excesses of silver bromide, which is
potentially incorporated into the structures through metal halide
bridge systems (Fig. 2). When a solvent mixture of dichloro-
methane–methanol (7 : 1) was used for the reaction, the resulting
isolated solids were signiﬁcantly more stable to air and found
not to contain excess silver bromide. Presumably the less polar
solvent causes the precipitation of silver bromide, hence the salt
does not become incorporated into the structure. The resonance
in the 1H NMR spectra attributable to the C2 proton disappears
upon deprotonation and resulting carbene formation, and a shift
at approximately 180 ppm in the 13C NMR spectra shows the C2
carbon coordinating to silver.
Reaction of imidazolium bromide salts 2 and 3 with silver
oxide to prepare neutral silver–NHC complexes, in which each
silver centre coordinates one NHC and one bromide atom, has
previously been reported.23,26 High resolution mass spectrometry
and elemental analytical data following our reaction conditions
are consistent with the formation of the cationic bis(NHC) com-
plexes depicted in Fig. 3.† Each silver coordinates to two NHC
centres with a non-coordinating bromide atom. Using the meta-
substituted ligands 2 and 3, it is possible for either a pincer (6
and 7) or polymeric complex to occur, whereas the para-substi-
tuted ligand is more likely to bridge two separate silver centres
(5). Literature precedence suggests that complexes 6 and 7 are
likely to form dinuclear or polynuclear complexes, with the
NHC moieties of each ligand twisting away from each other and
coordinating to different silver centres.23,26,27 NMR data of
complex 7 also shows the diastereotopic nature of the methylene
protons.
The in vitro cytotoxicity of silver bis(NHC) complexes 5–8
was determined using MTT-based assays involving a 6 day
drug-exposure period.28 Compounds were tested for their activity
against the human breast adenocarcinoma MCF7 and the colon
adenocarcinoma DLD1. In addition to chelating and macrocyclic
silver bis(NHCs) (5–7), the complex bearing the monodentate
ligand (8), imidazolium salts 1a and 2a, AgBr and AgBF4 were
also tested. The results are summarized in Table 1, Fig. 4 and
Fig. 5 and are compared to cisplatin.
The monodentate complex 8 against MCF7 (IC50 = 17.8 ±
3.8 μM) is clearly less effective than complexes bearing biden-
tate ligands (IC50 range including error = 1.5 to 9.7 μM). This
may be explained by the bidentate nature of the ligands render-
ing the complexes more stable. In a similar manner to antimicro-
bial silver NHCs, it is possible that increased stability results in a
slower release of silver so higher activity. The macrocyclic effect
generally leads to even higher complex stability relative to the
chelating effect. The macrocyclic complex 7, however, is less
cytotoxic than some of the chelating complexes (IC50 = 13.1 ±
4.8 μM). It is possible that a complex can become too stable and
doesn’t release sufﬁcient silver, hence becomes less efﬁcient
over the drug-exposure period.
Against MCF7, the bidentate complexes 5–6 show similar
IC50 values to each other suggesting that the N-substituent of the
ligand and the position of the NHC (meta or para) does not have
any considerable effect on cytotoxicity against this cell line.
Fig. 3 Silver bis(NHCs) 5–8. a: R = Me, X = Br; b: R = nPr, X = Br;
c: R = tBu, X = Br; d: R = Me, X = BF4.
Fig. 2 Metal halide bridge formation.
Scheme 1 Preparation of ligand precursors 1–4. a: R = Me, X = Br; b:
R = nPr, X = Br; c: R = tBu, X = Br; d: R = Me, X = BF4.
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 3720–3725 | 3721
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Against DLD1, however, it appears that the meta-chelating NHC
complexes (6) have enhanced cytotoxicity over the para-com-
plexes (5), with 6c in particular showing cytotoxicity values
superior to cisplatin (IC50 = 1.1 ± 0.2 μM for meta-6c vs. IC50 =
7.9 ± 0.9 μM for para-5c and 2.4 ± 1.0 μM for cisplatin). This
may again be due to complex stability, as the meta ligands are
able to chelate a silver centre whereas the para ligands are
unable to achieve the bite angle to do this. The N-tBu substituent
of 6c will also provide steric stability.
There is a hint of selectivity of 6a and 6c towards DLD1, pro-
viding the possibility of targeting (Fig. 5). These complexes
exhibit IC50 values against DLD1 in the same range as cisplatin,
whereas against MCF7 there is above a 4-fold increase in IC50
values compared to cisplatin. Surprisingly the counterion (Br− or
BF4
−) does not appear to have an effect on cytotoxicity values.
The counterion is expected to affect complex solubility and poss-
ible transmembrane diffusion, though this is likely to be very
subtle and the fact that all the complexes are cationic gives them
similar properties. AgBr, AgPF6 and imidazolium salts 1a and
2a exhibit IC50 values above 100 μM, which was the highest
concentration tested for these compounds, hence the synergistic
effect of both the silver centre and the NHC ligand clearly has a
role in the cytotoxicity of silver NHCs.
Conclusion
In conclusion, a series of monodentate, bidentate and macrocyc-
lic cationic silver bis(NHC) complexes have been prepared.
Their in vitro cytotoxicity has been assessed against the cancer-
ous cell lines MCF7 and DLD1. We have found that the com-
plexes display activity that is comparable to cisplatin, with those
bearing chelating ligands showing superior cytotoxic values
compared to their monodentate and macrocyclic counterparts.
The stability of the complex appears to have a role, with the
release rate of silver salt likely being the major factor in this. As
these complexes have activities comparable to cisplatin and are
likely to have a better toxicity proﬁle, they may prove valuable.
A major barrier to the continued development of these com-
pounds is the lack of a deﬁned mechanism of action or cancer
speciﬁc target. The data in Fig. 5 indicate that compounds 6a
and 6c are selectively exploiting some biological feature of
DLD1 cells and further studies are required to decipher mechan-
isms of action. We are extending our studies to conduct a cell
based screen designed to identify phenotypic and biochemical
effects of silver–NHC complexes on cells.
Experimental
General considerations
All reagents were used as supplied or prepared as outlined
without need for further puriﬁcation. N-substituted imidazoles,
imidazolium salts, and compound 5d were prepared according to
literature procedure.23,24,29 Manipulations were performed using
Fig. 4 Response of MCF7 (top) and DLD1 (bottom) cell lines to cis-
platin and silver complexes. Values presented are IC50 (μM) ± SD for
three independent experiments.
Fig. 5 Response of MCF7 and DLD1 to cisplatin and meta-substituted
silver complexes 6a and 6c. Values presented are IC50 (μM).
Table 1 Response of MCF7 and DLD1 cell lines to cisplatin, silver
salts, imidazolium salts and silver complexes. Values presented are IC50
(μM) ± SD for three independent experiments
Compound MCF7 DLD1
Cisplatin 1.3 ± 0.7 2.4 ± 1.0
AgBr >100 >100
AgBF4 >100 >100
1a >100 >100
2a >100 >100
5a 6.3 ± 2.2 4.1 ± 0.6
5b 5.6 ± 4.1 5.4 ± 0.4
5c 4.3 ± 0.3 7.9 ± 0.9
5d 3.5 ± 0.1 4.6 ± 0.3
6a 7.9 ± 0.8 2.3 ± 1.3
6c 4.2 ± 0.5 1.1 ± 0.2
7 13.1 ± 4.8 —
8 17.8 ± 3.8 —
3722 | Dalton Trans., 2012, 41, 3720–3725 This journal is © The Royal Society of Chemistry 2012
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standard Schlenk line and vacuum line techniques. N2 was
passed through a twin-column drying apparatus containing mol-
ecular sieves (4 Å) and potassium hydroxide. Solvents were
passed over activated alumina to remove water, copper catalyst to
remove oxygen and molecular sieves to remove any remaining
water via the Dow–Grubbs solvent system. 1H and 13C NMR
spectra were recorded on a Bruker DPX300 spectrometer (oper-
ating frequency 300.1 MHz for 1H and 75.48 MHz for 13C) or
on a Bruker DRX500 spectrometer (operating frequency
500.13 MHz for 1H and 125.80 MHz for 13C). All spectra were
recorded at 298 K in deuterated solvent. Chemical shift values
are quoted in parts per million (ppm, δ) and coupling constants J
are quoted in Hertz (Hz). Assignment of 1H NMR spectra was
aided by the use of 2D 1H1H COSY experiments and the assign-
ment of 13C{1H} NMR spectra was aided by 13C{1H} dept 135
experiments. Microanalyses were performed by Mr Ian Blakeley
in the University of Leeds, School of Chemistry. Mass spectra
were collected by Ms Tanya Marinko-Covell either on a Bruker
Daltonics (micro TOF) instrument operating in the electrospray
mode or a GCT Premier (TOF) instrument operating in electron
impact mode using methanol or acetonitrile as solvent.
Ag(NHC)Br (5a)
1a (522 mg, 1.24 mmol) was added to DCM (7 mL) giving a
white suspension. To the suspension was added MeOH (1 mL)
to give a clear solution to which was added Ag2O (432 mg,
1.86 mmol) and 3 Å molecular sieves. The mixture was stirred
for 18 hours in the dark to give a light brown precipitate (AgBr).
This was ﬁltered through Celite and the solvent removed from
the ﬁltrate in vacuo to give an off white solid. Yield: 443 mg
(79%). 1H NMR (d4-MeOD, 500 MHz) δ: 7.32 (s, 8H, CH),
7.11 (s, 8H, ArH), 5.20 (s, 8H, CH2), 3.91 (s, 12H, CH3).
13C
NMR (d4-MeOD, 75 MHz) δ: 182.9 (br d, C–Ag), 136.44 (CH),
128.51 (C), 122.96 (CH), 122.69 (CH), 54.28 (CH2), 38.51
(CH3). MS (ESI
+): m/z 374.1 [M − 2Br]2+. Calcd for
C16H18N4Ag [M − 2Br]
2+: 373.0582. Found: 373.0591. Anal.
Calcd for C32H36Ag2Br2N8: C, 42.32; H, 4.00; N, 12.34. Found:
C, 43.05; H, 4.25; N, 11.90.†
Ag(NHC)Br (5b)
1b (500 mg, 1.03 mmol) was added to DCM (7 mL) giving a
white suspension. To the suspension was added MeOH (1 mL)
to give a clear solution to which was added Ag2O (359 mg,
1.55 mmol) and 3 Å molecular sieves. The mixture was stirred
for 18 hours in the dark to give a light brown precipitate (AgBr).
This was ﬁltered through Celite and the solvent removed from
the ﬁltrate in vacuo to give an off white solid. Yield: 173 mg
(33%). 1H NMR (d4-MeOD, 300 MHz) δ: 7.38 (d,
3J = 1.7 Hz,
4H, CH), 7.34 (d, 3J = 1.7 Hz, 4H, CH), 7.09 (s, 8H, ArH), 5.21
(s, 8H, CH2), 4.18 (t,
3J = 7.2 Hz, 8H, CH2), 2.01–1.84 (m, 8H,
CH2), 0.95 (t,
3J = 7.2 Hz, 12H, CH3).
13C NMR (d4-MeOD,
75 MHz) δ: Ag–C not observed, 139.03 (CH), 129.29 (C),
123.82 (CH), 123.66 (CH), 55.80 (CH2), 54.96 (CH2), 26.49
(CH2), 11.84 (CH3). MS (ESI
+): m/z 430.1 [M − 2Br]2+. HRMS
(ESI+): Calcd for C20H26N4Ag [M − 2Br]
2+: 429.1208. Found:
429.1204. Anal. Calcd for C40H52Ag2Br2N8: C, 47.08; H, 5.14;
N, 10.98. Found: C, 48.75; H, 5.70; N, 10.80.†
Ag(NHC)Br (5c)
1c (1 g, 1.95 mmol) was added to DCM (14 mL) giving a white
suspension. To the suspension was added MeOH (2 mL) to give
a clear solution to which was added Ag2O (679 mg, 2.93 mmol)
and 3 Å molecular sieves. The mixture was stirred for 18 hours
in the dark to give a light brown precipitate (AgBr). This was
ﬁltered through Celite and the solvent removed from the ﬁltrate
in vacuo to give an off white solid. Yield: 550 mg (70%). 1H
NMR (d4-MeOD, 500 MHz) δ: 7.56 (s, 4H, CH), 7.21 (s, 4H,
CH), 6.97 (s, 8H, ArH), 5.26 (s, 8H, CH2), 1.81 (s, 36H, CH3).
13C NMR (d4-MeOD, 75 MHz) δ: Ag–C not observed, 138.59
(CH), 128.85 (C), 122.31 (CH), 121.98 (CH), 59.56 (C), 56.86
(CH2), 32.63 (CH3). MS (ESI
+): m/z 458.2 [M − 2Br]2+. HRMS
(ESI+): Calcd for C22H30N4Ag [M − −2Br]
2+: 457.1521. Found:
457.1511. Anal. Calcd for C44H60Ag2Br2N8: C, 49.09; H, 5.62;
N, 10.41. Found: C, 50.20; H, 6.10; N, 10.25.†
Ag(NHC)Br (6a)
2a (1 g, 2.33 mmol) was added to DCM (14 mL) giving a white
suspension. To the suspension was added MeOH (2 mL) to give
a clear solution to which was added Ag2O (812 mg, 3.50 mmol)
and 3 Å molecular sieves. The mixture was stirred for 18 hours
in the dark to give a light brown precipitate (AgBr). This was
ﬁltered through Celite and the solvent removed from the ﬁltrate
in vacuo to give an off white solid. Yield: 728 mg (69%). 1H
NMR (d4-MeOD, 500 MHz) δ: 7.34 (br, 5H, CH & ArH), 7.16
(m, 3H, ArH), 5.19 (s, 4H, CH2), 3.75 (s, 6H, CH3).
13C NMR
(d4-MeOD, 75 MHz) δ: 181.04 (br d, C–Ag), 139.59 (C),
131.30 (CH), 130.01 (CH), 128.86 (CH), 124.50 (CH), 124.07
(CH), 55.77 (CH2), 39.40 (CH3). MS (ESI
+): m/z 374.1 [M −
Br]+. HRMS (ESI+): Calcd for C16H18N4Ag [M − Br]
+:
373.0582. Found: 373.0562. Anal. Calcd for C16H18AgBrN4: C,
42.32; H, 4.00; N, 12.34. Found: C, 42.89; H, 4.19; N, 11.93.†
Ag(NHC)Br (6c)
2c (1.2 g, 2.34 mmol) was added to DCM (14 mL) giving a
white suspension. To the suspension was added MeOH (2 mL)
to give a clear solution to which was added Ag2O (814 mg,
3.51 mmol) and 3 Å molecular sieves. The mixture was stirred
for 18 hours in the dark to give a light brown precipitate (AgBr).
This was ﬁltered through Celite and the solvent removed from
the ﬁltrate in vacuo to give an off white solid. Yield: 980 mg
(78%). 1H NMR (d4-MeOD, 500 MHz) δ: 7.58 (s, 2H, CH),
7.29 (t, 3J = 7.6 Hz, 1H, ArH), 7.22 (s, 2H, CH), 6.95 (d, 3J =
7.6 Hz, 2H, ArH), 6.85 (s, 1H, ArH), 5.20 (s, 4H, CH2), 1.80
(s, 18H, CH3).
13C NMR (d4-MeOD, 75 MHz) δ: 180.34 (br
d, C–Ag), 139.64 (C), 131.25 (CH), 127.86 (CH), 126.69 (CH),
122.54 (CH), 121.92 (CH), 59.57 (C), 56.93 (CH2), 32.65
(CH3). MS (ESI
+): m/z 458.2 [M − Br]+. HRMS (ESI+): Calcd
for C22H30N4Ag [M − Br]
+: 457.1521. Found: 457.1514. Anal.
Calcd for C22H30AgBrN4: C, 49.09; H, 5.62; N, 10.41. Found:
C, 50.60; H, 6.65; N, 10.10.†
This journal is © The Royal Society of Chemistry 2012 Dalton Trans., 2012, 41, 3720–3725 | 3723
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Ag(NHC)Br (7)
3 (1.00 g, 2.00 mmol) was added to DCM (14 mL) giving a
white suspension. To the suspension was added MeOH (2 mL)
to give a clear solution to which was added Ag2O (692 mg,
3.00 mmol) and 3 Å molecular sieves. The mixture was stirred
for 24 hours in the dark to give a light brown precipitate (AgBr).
The mixture was ﬁltered through Celite and the solvent removed
from the ﬁltrate in vacuo to give a yellow oil. This was triturated
with Et2O to give a white solid. Yield: 712 mg (67%).
1H NMR
(d4-MeOD, 500 MHz) δ: 7.14 (d,
3J = 7.6 Hz, 4H, ArH), 7.09
(s, 2H, CH), 7.09 (s, 2H, CH), 7.06 (t, 3J = 7.6 Hz, 2H, ArH),
7.06 (s, 2H, ArH), 5.18 (d, 2J = 16.2 Hz, 4H, CH2), 5.18 (d,
2J =
16.2 Hz, 4H, CH2).
13C NMR (d4-MeOD, 75 MHz) δ: 183.57
(dd, 1JC-107-Ag = 179 Hz,
1JC-109-Ag = 207 Hz), 139.48 (C),
130.66 (CH), 128.02 (CH), 124.57 (CH), 124.50 (CH), 122.80
(CH), 55.56 (CH2). MS (ESI
+): m/z 448.1 [M − Br]+. HRMS
(ESI+): Calcd for C22H20N4Ag [M − Br]
+: 447.0739. Found:
447.0714. Anal. Calcd for C22H20AgBrN4: C, 50.03; H, 3.82; N,
10.61. Found: C, 50.65; H, 4.50; N, 9.95.†
Ag(NHC)2AgBr2 (8)
4 (545 mg, 2.15 mmol) was dissolved in DCM (22 mL) and
Ag2O (249 mg, 1.08 mmol) was added. The mixture was stirred
for 18 hours in the dark. The mixture was ﬁltered through Celite
and the solvent removed from the ﬁltrate in vacuo to give an oil.
This was triturated with Et2O to give a white solid. Yield:
0.502 g (65%). 1H NMR (d6-DMSO, 300 MHz) δ: 7.54 (d,
3J =
1.73 Hz, 2H, CH), 7.45 (d, 3J = 1.73 Hz, 2H, CH), 7.38–7.27
(m, 10H, ArH), 5.31 (s, 4H, CH2), 3.77 (s, 6H, CH3).
13C NMR
(d6-DMSO, 75 MHz) δ: Ag–C not observed, 137.68 (C), 129.10
(CH), 128.32 (CH), 127.95 (CH), 123.61 (CH), 122.52 (CH),
54.35 (CH2), 38.51 (CH3). MS (ESI
+): m/z 452.1 [M − Br]+.
HRMS (ESI+): Calcd for C22H24N4Ag [M − Br]
+: 451.1052.
Found: 451.1045. Anal. Calcd for C22H24AgBrN4·AgBr: C,
36.70; H, 3.36; N, 7.78. Found: C, 37.85; H, 3.45; N, 7.95.†
Cytotoxicity studies
In vitro cell tests were performed at the Institute of Cancer
Therapeutics, Bradford, on the MCF7 (human adenocarcinoma
of the breast) and DLD1 (human adenocarcinoma of the colon)
cell lines. Cells were incubated in 96-well plates, at 2 × 103 cells
per well in 200 μL of growth media (RPMI 1640 supplemented
with 10% foetal calf serum, sodium pyruvate (1 mM) and L-glu-
tamine (2 mM)). Cells were incubated for 24 hours at 37 °C in
an atmosphere of 5% CO2 prior to drug exposure. Silver com-
pounds, imidazolium salts and cisplatin were dissolved in
dimethylsulphoxide at a concentration of 25 mM and diluted
with medium to obtain drug solutions ranging from 25 to
0.049 μM. The ﬁnal dimethylsulphoxide concentration was 0.1%
(v/v) which is non-toxic to cells. Drug solutions were applied to
cells and incubated for 6 days at 37 °C in an atmosphere of 5%
CO2. The solutions were removed from the wells and fresh
medium added to each well along with 20 μL MTT (5 mg
mL−1), and incubated for 4 hours at 37 °C in an atmosphere of
5% CO2. The solutions were removed and 150 μL dimethyl-
sulphoxide was added to each well to dissolve the purple
formazan crystals. A plate reader was used to measure the absor-
bance at 540 nm. Lanes containing medium only, and cells in
medium only (no drug), were used as blanks for the spectropho-
tometer and 100% cell survival respectively. Cell survival was
determined as the absorbance of treated cells divided by the
absorbance of controls and expressed as a percentage. The con-
centration required to kill 50% of cells (IC50) was determined
from plots of % survival against drug concentration. Each exper-
iment was repeated 3 times and a mean value obtained. In the
cases where an IC50 value was not obtained (AgBr, AgBF4, 1a,
2a) experiments were repeated using a higher concentration of
drug up to a maximum of 100 μM. Response of MCF7 and
DLD1 cell lines to cisplatin, silver compounds and imidazolium
salts are presented in the table below as IC50 (μM) ± SD for
three independent experiments.
Notes and references
†Elemental analytical data gives carbon content slightly higher than
expected for all the complexes. NMR spectroscopy and mass spec-
trometry data do not indicate impurities, and a higher than expected
carbon value is clearly not a result of excess silver bromide The likely
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